VolitionRx Ltd (VNRX) stock
VNRXNYSEIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$0.18−0.01 (-3.02%)
Close on Nov 18, 2026Market cap $2.50MP/E –Yield –
VolitionRx operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
VolitionRx's operating income for the twelve months ending Jun 30, 2026 was -$19.42M. For fiscal 2025 it was -$21.74M. The highest annual figure on record is -$2.61M in fiscal 2011.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$21.74M | – |
| FY2024 | Dec 31, 2024 | -$27.02M | – |
| FY2023 | Dec 31, 2023 | -$35.99M | – |
| FY2022 | Dec 31, 2022 | -$31.78M | – |
| FY2021 | Dec 31, 2021 | -$28.33M | – |
| FY2020 | Dec 31, 2020 | -$21.25M | – |
| FY2019 | Dec 31, 2019 | -$16.04M | – |
| FY2018 | Dec 31, 2018 | -$17.90M | – |
| FY2017 | Dec 31, 2017 | -$14.70M | – |
| FY2016 | Dec 31, 2016 | -$12.43M | – |
| FY2015 | Dec 31, 2015 | -$10.01M | – |
| FY2014 | Dec 31, 2014 | -$5.95M | – |
| FY2013 | Dec 31, 2013 | -$4.58M | – |
| FY2012 | Dec 31, 2012 | -$4.08M | – |
| FY2011 | Dec 31, 2011 | -$2.61M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.16M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.35M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.82M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.10M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.30M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.52M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.78M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.87M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.99M | – |
| Q1 FY2024 | Mar 31, 2024 | -$8.38M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.74M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.65M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.55M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.05M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.01M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.99M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.10M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.68M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.79M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.56M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.90M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.09M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.66M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.50M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.21M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.87M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.72M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.18M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.15M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.99M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.26M | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.45M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.57M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.63M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.04M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.88M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.44M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.34M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.48M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.48M | – |
See a number that looks wrong?